View Alert


Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: 09-Feb-2021 16:00:45

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities Trusts
  • Acute Trusts
  • Community Trusts

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Social Care Providers (registered with CAS)
  • Special Health Authorities
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Phyllocontin (Aminophylline) 225mg and 350mg modified release tablets

Broadcast content:
Phyllocontin® (aminophylline) Continus 225mg and Phyllocontin® Forte Continus 350mg modified-release tablets are being discontinued in the UK.  

Remaining supplies of the 225mg strength are expected to be exhausted by 2nd March 2021 and the 350mg strength are expected to be exhausted by 5th April 2021.

Phyllocontin® (aminophylline) is used in adults for the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis.  For children, it is used for the management of asthma. 

Prescribers will need to review all affected patients and optimise inhaled therapies.  Patients who still require a methylxanthine, will need to be switched to theophylline tablets (Uniphyllin Continus®). 

This alert contains further information and action for providers.

Please note that no response is required via the CAS website to this alert.


Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy

Alert reference: SDA/2021/003

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency